335 related articles for article (PubMed ID: 26546268)
1. The Wnts of change: How Wnts regulate phenotype switching in melanoma.
Webster MR; Kugel CH; Weeraratna AT
Biochim Biophys Acta; 2015 Dec; 1856(2):244-51. PubMed ID: 26546268
[TBL] [Abstract][Full Text] [Related]
2. Hierarchy of TGFβ/SMAD, Hippo/YAP/TAZ, and Wnt/β-catenin signaling in melanoma phenotype switching.
Lüönd F; Pirkl M; Hisano M; Prestigiacomo V; Kalathur RK; Beerenwinkel N; Christofori G
Life Sci Alliance; 2022 Feb; 5(2):. PubMed ID: 34819356
[TBL] [Abstract][Full Text] [Related]
3. The role of Wnt/β-catenin signaling pathway in melanoma epithelial-to-mesenchymal-like switching: evidences from patients-derived cell lines.
Kovacs D; Migliano E; Muscardin L; Silipo V; Catricalà C; Picardo M; Bellei B
Oncotarget; 2016 Jul; 7(28):43295-43314. PubMed ID: 27175588
[TBL] [Abstract][Full Text] [Related]
4. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.
Sinnberg T; Levesque MP; Krochmann J; Cheng PF; Ikenberg K; Meraz-Torres F; Niessner H; Garbe C; Busch C
Mol Cancer; 2018 Feb; 17(1):59. PubMed ID: 29454361
[TBL] [Abstract][Full Text] [Related]
5. Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.
O'Connell MP; Weeraratna AT
Pigment Cell Melanoma Res; 2009 Dec; 22(6):724-39. PubMed ID: 19708915
[TBL] [Abstract][Full Text] [Related]
6. Microenvironment-derived factors driving metastatic plasticity in melanoma.
Kim IS; Heilmann S; Kansler ER; Zhang Y; Zimmer M; Ratnakumar K; Bowman RL; Simon-Vermot T; Fennell M; Garippa R; Lu L; Lee W; Hollmann T; Xavier JB; White RM
Nat Commun; 2017 Feb; 8():14343. PubMed ID: 28181494
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
O'Connell MP; Marchbank K; Webster MR; Valiga AA; Kaur A; Vultur A; Li L; Herlyn M; Villanueva J; Liu Q; Yin X; Widura S; Nelson J; Ruiz N; Camilli TC; Indig FE; Flaherty KT; Wargo JA; Frederick DT; Cooper ZA; Nair S; Amaravadi RK; Schuchter LM; Karakousis GC; Xu W; Xu X; Weeraratna AT
Cancer Discov; 2013 Dec; 3(12):1378-93. PubMed ID: 24104062
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effects of differentiation-inducing factor-1 in malignant melanoma: GSK-3-mediated inhibition of cell proliferation and GSK-3-independent suppression of cell migration and invasion.
Arioka M; Takahashi-Yanaga F; Kubo M; Igawa K; Tomooka K; Sasaguri T
Biochem Pharmacol; 2017 Aug; 138():31-48. PubMed ID: 28501501
[TBL] [Abstract][Full Text] [Related]
9. A Wnt-er migration: the confusing role of β-catenin in melanoma metastasis.
Webster MR; Weeraratna AT
Sci Signal; 2013 Mar; 6(268):pe11. PubMed ID: 23532332
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
[TBL] [Abstract][Full Text] [Related]
11. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
12. Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights.
Xue G; Romano E; Massi D; Mandalà M
Cancer Treat Rev; 2016 Sep; 49():1-12. PubMed ID: 27395773
[TBL] [Abstract][Full Text] [Related]
13. Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells.
Vaid M; Prasad R; Sun Q; Katiyar SK
PLoS One; 2011; 6(7):e23000. PubMed ID: 21829575
[TBL] [Abstract][Full Text] [Related]
14. Noncanonical Wnt signaling plays an important role in modulating canonical Wnt-regulated stemness, proliferation and terminal differentiation of hepatic progenitors.
Fan J; Wei Q; Liao J; Zou Y; Song D; Xiong D; Ma C; Hu X; Qu X; Chen L; Li L; Yu Y; Yu X; Zhang Z; Zhao C; Zeng Z; Zhang R; Yan S; Wu T; Wu X; Shu Y; Lei J; Li Y; Zhang W; Haydon RC; Luu HH; Huang A; He TC; Tang H
Oncotarget; 2017 Apr; 8(16):27105-27119. PubMed ID: 28404920
[TBL] [Abstract][Full Text] [Related]
15. RAD6B Loss Disrupts Expression of Melanoma Phenotype in Part by Inhibiting WNT/β-Catenin Signaling.
Sarma A; Gajan A; Kim S; Gurdziel K; Mao G; Nangia-Makker P; Shekhar MPV
Am J Pathol; 2021 Feb; 191(2):368-384. PubMed ID: 33181138
[TBL] [Abstract][Full Text] [Related]
16. In the Wnt-er of life: Wnt signalling in melanoma and ageing.
Kaur A; Webster MR; Weeraratna AT
Br J Cancer; 2016 Nov; 115(11):1273-1279. PubMed ID: 27764844
[TBL] [Abstract][Full Text] [Related]
17. The WNT/Beta-catenin pathway in melanoma.
Larue L; Delmas V
Front Biosci; 2006 Jan; 11():733-42. PubMed ID: 16146765
[TBL] [Abstract][Full Text] [Related]
18. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching.
Eichhoff OM; Weeraratna A; Zipser MC; Denat L; Widmer DS; Xu M; Kriegl L; Kirchner T; Larue L; Dummer R; Hoek KS
Pigment Cell Melanoma Res; 2011 Aug; 24(4):631-42. PubMed ID: 21599871
[TBL] [Abstract][Full Text] [Related]
19. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities.
Xu X; Zhang M; Xu F; Jiang S
Mol Cancer; 2020 Nov; 19(1):165. PubMed ID: 33234169
[TBL] [Abstract][Full Text] [Related]
20. [Nuclear beta-catenin localization is not sufficient for canonical Wnt signaling activation in human meianoma cell lines].
Kulikova KV; Posviatenko AV; Gnuchev NV; Georgiev GP; Kibardin AV; Larin SS
Mol Biol (Mosk); 2011; 45(5):884-91. PubMed ID: 22393786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
